20% Off Everything · No Code NeededThird-Party Tested at the Source LabShips Within 1 Business Day · TrackedU.S. Sourced · U.S. ShippedFree 2-Day Shipping at $1,000 and Over≥99% Purity — HPLC + Mass SpecLot-Matched Certificate on File for Every Lot We Ship20% Off Everything · No Code NeededThird-Party Tested at the Source LabShips Within 1 Business Day · TrackedU.S. Sourced · U.S. ShippedFree 2-Day Shipping at $1,000 and Over≥99% Purity — HPLC + Mass SpecLot-Matched Certificate on File for Every Lot We Ship
For Laboratory & Research Use Only — Not for Human or Veterinary Use
All ProductsGLP-1 & MetabolicResearch PeptidesPeptide BlendsNasal SpraysDissolving StripsBioregulatorsResearch BundlesLab Supplies Search

Sermorelin Over Time: What the Trials Measured at Week 4, 8 and 12 (IGF-1, Body Composition, Sleep Architecture)

Sermorelin Over Time: What the Trials Measured at Week 4, 8 and 12 (IGF-1, Body Composition, Sleep Architecture)

Published sermorelin (GHRH 1-29) trials that followed participants over several weeks generally measured three endpoints on a recurring schedule: serum GH pulse characteristics and IGF-1 at early and late timepoints, body composition at the start and end of the study period, and, in a smaller subset of the literature, sleep EEG architecture. The pattern across these trials is an early hormonal response followed by a slower, smaller downstream change in body composition.

Key factDetailSource
Earliest measurable changeGH pulse amplitude and 24-hour GH secretion, detectable within the first study weeks of repeated administrationCorpas, Harman and Blackman, 1993 (PubMed PMID 8491152)
Downstream endpointIGF-1, which rises more slowly than the acute GH pulse because it reflects cumulative hepatic GH exposureCorpas, Harman and Blackman, 1993 (PubMed PMID 8491152)
Slowest-moving endpointBody composition (lean mass, fat mass), typically assessed only at study start and study end rather than at intermediate weeksCorpas, Harman and Blackman, 1993 (PubMed PMID 8491152)
Typical older-adult study duration in this literatureSeveral weeks of repeated subcutaneous administration, consistent with the trial designs this review synthesizesCorpas, Harman and Blackman, 1993 (PubMed PMID 8491152)
Pediatric timeline endpointGrowth velocity, assessed over months rather than weeks because linear growth is a slow-accruing measurementWalker, 2006 (PubMed PMID 18046908)

What changes earliest in a sermorelin study timeline?

The GH pulse response is the earliest measurable change across the GHRH(1-29) literature. Because GHRH(1-29) acts directly on the pituitary receptor, a change in pulse amplitude and in 24-hour integrated GH secretion can appear within the first days to weeks of a repeated-administration regimen, well before any downstream tissue effect would be expected to show up on a body-composition scan. Researchers studying older adults used this early hormonal signal to confirm that a given administration schedule was pharmacologically active before continuing the study long enough to look for slower-moving endpoints.

What does the literature report changing by mid-study timepoints?

IGF-1 is the endpoint most associated with mid-study timepoints in this literature, because it is generated in the liver in response to sustained GH exposure rather than reflecting a single pulse. Trials following participants for several weeks generally reported IGF-1 continuing to track upward over that period as repeated GH pulses accumulated their downstream hepatic effect, a slower trajectory than the GH pulse data itself. This lag between an immediate pituitary readout and a slower hepatic readout is a recurring structural feature of how this literature reports its data, not unique to any single trial.

Timeline: what was measured at which point in the published studies

Approximate study timepointEndpoint measuredWhat the literature reportsSource
Early (first one to two weeks of repeated administration)GH pulse amplitude, 24-hour GH secretionDetectable rise in pulse amplitude relative to baseline, confirming pharmacologic activity of the administration scheduleCorpas, Harman and Blackman, 1993 (PMID 8491152)
Early to mid (several weeks in)IGF-1Progressive rise toward levels associated with a younger comparison group in several of the trials this review synthesizesCorpas, Harman and Blackman, 1993 (PMID 8491152)
Mid (study midpoint, where assessed)Tolerability and routine safety panelsPeriodic clinical review and laboratory panels repeated at intervals through the administration periodCorpas, Harman and Blackman, 1993 (PMID 8491152)
End of study (study close, generally several weeks to a few months after start in the older-adult literature)Body composition (lean mass, fat mass)Modest shifts reported relative to baseline, smaller in magnitude and later in onset than the hormonal changesCorpas, Harman and Blackman, 1993 (PMID 8491152)
Pediatric timeline (months, not weeks)Growth velocity, bone ageTracked over a longer observation window appropriate to the slow rate of linear growthWalker, 2006 (PMID 18046908)
Single-timepoint acute readout (same day)Serum GH by routeEvans et al., 1985 compared intravenous, subcutaneous and intranasal GHRH(1-29) on the same acute timeline rather than across weeks, establishing the single-timepoint comparison this literature uses before moving to multi-week designsEvans et al., 1985
First multi-week primary trial in older menGH, IGF-1Corpas et al., 1992 tracked twice-daily subcutaneous administration across a multi-week timeline in older men, one of the primary trials the Corpas 1993 review above synthesizesCorpas et al., 1992
Single nightly-injection timelineOvernight GH secretion, IGF-1Vittone et al., 1997 tracked a once-nightly subcutaneous regimen, reporting overnight GH and IGF-1 changes across its study periodVittone et al., 1997
Long-term administration timelineEndocrine, metabolic and immune markersKhorram et al., 1997 extended the administration timeline further than most of the studies above, tracking immune-function markers over the long-term periodKhorram et al., 1997
Pediatric multicenter first-year timelineGrowth velocityThorner et al., 1996 (Geref International Study Group) tracked growth velocity across the first year of once-daily therapy, the longest timeline in this tableThorner et al., 1996

The consistent pattern in this table is a cascade: an acute pituitary signal first, a downstream hepatic signal (IGF-1) over the following weeks, and a tissue-level signal (body composition or growth velocity) only once that hormonal exposure has accumulated for an extended period. A study stopped early would capture the first stage and miss the later ones entirely, which is part of why trial duration itself is a meaningful variable when comparing papers in this literature. The earliest human timeline in this record, Thorner and colleagues' 1985 case series following two growth-hormone-deficient children, used a growth-velocity timeline measured in months, the same long-horizon approach the later Geref International trial scaled up to a full multicenter program. The pulsatile pattern underlying all of these timelines is described at the mechanistic level in Frohman and Jansson's 1986 review of GHRH pharmacology, which remains the standard reference for why a GHRH(1-29) timeline looks like a series of discrete pulses rather than a smooth curve.

What does the literature say about sleep architecture over time?

A smaller body of GHRH(1-29) pharmacology work used overnight sleep EEG as an endpoint, because GHRH administration has been linked to changes in slow-wave sleep in some of this research. Where sleep EEG was used, it was typically assessed on administration nights within a short study window rather than across a multi-week timeline, which makes it a different kind of endpoint from IGF-1 or body composition: a same-night physiological readout rather than a cumulative one. Readers comparing a sleep-EEG finding against a multi-week body-composition finding from a different trial are looking at two different timescales of measurement, not two results that should be expected to move together.

Why does body composition move more slowly than the hormonal endpoints?

Body composition integrates weeks of metabolic exposure into a single measurement, so it necessarily lags behind the acute hormonal signal that drives it. A single GH pulse does not meaningfully change lean mass or fat mass on its own; it is the cumulative effect of many pulses, mediated through IGF-1 and direct GH action on adipose and muscle tissue, that eventually produces a measurable shift. This is why the trials in this literature that report body-composition data almost always pair a short-duration hormonal readout with a longer-duration tissue readout rather than relying on body composition alone to judge whether an administration schedule was pharmacologically active.

How do study design choices affect what a timeline can show?

Three design choices shape what a sermorelin timeline paper can actually demonstrate. Sampling frequency for GH itself is the first: because GH release is pulsatile, a single daily blood draw can miss a pulse entirely, so the trials that reported precise pulse-amplitude data generally used frequent overnight sampling rather than a single morning measurement, while trials relying on a single timepoint per visit are better suited to tracking IGF-1, which does not fluctuate pulse to pulse. Washout and baseline stabilization is the second: several of the older-adult trials summarized in the Corpas review built in a baseline period before starting administration specifically so that a participant's own pre-study hormonal pattern, not a population average, served as the comparison point for every later timepoint. Comparator group design is the third: trials comparing an older-adult group against a younger reference group used the same sampling schedule in both groups so that any difference at a given week reflected a real age-related difference rather than a difference in how often each group was sampled.

These design choices are also why cross-study comparisons need care. A trial that samples GH every twenty minutes overnight and a trial that draws GH once in the morning are not measuring the same thing, even though both report a number labeled serum GH, and a reader lining up two papers' week-4 data side by side should check the sampling design before treating the two figures as directly comparable.

What happens after a sermorelin study ends?

Several of the older-adult trials summarized in the secondary literature included a follow-up assessment after administration stopped, to see whether the GH-axis and body-composition changes persisted or reverted toward the pre-study baseline. The general pattern reported is a reversion of the acute hormonal signal, GH pulse amplitude moving back toward baseline relatively quickly once administration ends, consistent with GHRH(1-29)'s short circulating presence and the pituitary's return to its prior pattern of endogenous GHRH and somatostatin signaling. Whether the slower body-composition changes persisted, partially reverted, or fully reverted is reported with less consistency across the literature, in part because fewer trials included a long enough post-administration follow-up window to answer that question definitively.

How does this timeline compare with other GH-axis research peptides?

Growth Hormone Secretagogues in Research lays out how ipamorelin, CJC-1295, sermorelin, and TH9507 are studied on comparable hormonal and tissue timelines, which is useful context for comparing a sermorelin study against a trial using a different secretagogue. Sermorelin vs TH9507 vs CJC-1295 compares the half-life differences between these GHRH analogs, which is one reason study designs vary in how frequently they administer each compound within a given timeline.

How is sermorelin handled across a multi-week research timeline?

A study that spans several weeks depends on consistent material from the first administration to the last. Reconstituting Lyophilized Peptides: The Math, Step by Step covers how to prepare a reconstituted solution the same way at each study timepoint so that the preparation itself is not an uncontrolled variable across the timeline. How to Read a Peptide Certificate of Analysis explains how to confirm a lot's identity and purity before a multi-week study begins, since a lot change partway through a timeline without re-verification would confound exactly the kind of week-to-week comparison this literature depends on. Homegrown's sermorelin listing documents each lot for this reason.

Frequently asked questions

What is the first endpoint to change in a sermorelin study timeline?

GH pulse amplitude and 24-hour GH secretion, which can shift within the first weeks of repeated administration because they are a direct pituitary readout.

How long does it take for IGF-1 to change in these trials?

The published older-adult literature describes a progressive rise over the administration period rather than an immediate jump, consistent with IGF-1 reflecting cumulative rather than acute GH exposure.

Why is body composition usually measured only at the start and end of a study?

Because it is a slow-moving, cumulative endpoint; measuring it at intermediate weeks would mostly capture measurement noise rather than a meaningful physiological change over such a short interval.

Do sleep-architecture findings follow the same weekly timeline as IGF-1?

No. Where sleep EEG was used as an endpoint, it was generally assessed on individual administration nights rather than tracked across a multi-week timeline, so it is not directly comparable to the IGF-1 or body-composition data from the same or other trials.

Is the pediatric growth-velocity timeline the same as the adult IGF-1 timeline?

No. Growth velocity is tracked over months because linear growth accrues slowly, while adult IGF-1 and GH-pulse data in this literature are generally tracked over weeks.

Does stopping a study early change what it can show?

Yes, based on the cascade described in this literature: an early stop can capture the acute GH-pulse signal while missing the slower IGF-1 and body-composition changes that take longer to appear.

Where can I check whether a research lot stayed consistent across a multi-week study?

On its certificate of analysis for each lot used. How to Read a Peptide Certificate of Analysis explains what to check.

References

  1. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocrine Reviews. 1993;14(1):20-39. PubMed PMID 8491152.
  2. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308. PubMed PMID 18046908.
  3. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-587. PubMed PMID 6812220.
  4. Evans WS, Borges JL, Kaiser DL, Vance ML, Sellers RP, MacLeod RM, Vale W, Rivier J, Thorner MO. Effects of intravenous, subcutaneous, and intranasal administration of growth hormone-releasing hormone-(1-29) on serum growth hormone concentrations in normal men. Journal of Clinical Endocrinology and Metabolism. 1985;61(5):846-850. PubMed PMID.
  5. Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology and Metabolism. 1992;75(2):530-535. PubMed PMID.
  6. Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. PubMed PMID.
  7. Khorram O, Vu L, Yen SS. Activation of immune function by [GHRH(1-29)]-NH2 in age-advanced men and women. Journal of Gerontology: Biological Sciences. 1997;52(5):M267-M274. PubMed PMID.
  8. Thorner MO, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Thompson MH, Mettler P. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. Journal of Clinical Endocrinology and Metabolism. 1996;81(3):1189-1196. PubMed PMID.
  9. Thorner MO, Reschke J, Chitwood J, et al. Acceleration of growth in two children treated with human growth hormone-releasing factor. Lancet. 1985;1(8419):4-6. PubMed PMID.
  10. Frohman LA, Jansson JO. Growth hormone-releasing hormone. Endocrine Reviews. 1986;7(3):223-253. PubMed PMID.

Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.

← Back to the blog